Over the past decade, the pharmaceutical industry has shifted remarkably due to the changing needs of customers impacting demand for pharmaceutical products on a global scale. As such, contract development and manufacturing organisations (CDMOs) are implementing merger and acquisition (M&A) strategies in order to meet market requirements and increase their competitiveness. Mark Quick at Recipharm discusses the proliferation of M&As across the pharmaceutical industry, exploring the key drivers of this activity and how consolidation will impact the landscape for CDMOs going forward.